-+ 0.00%
-+ 0.00%
-+ 0.00%
Savara Presents Phase 3 Data Showing MOLBREEVI Improves Lung Function in Autoimmune PAP
Share
Listen to the news
Savara Presents Phase 3 Data Showing MOLBREEVI Improves Lung Function in Autoimmune PAP
  • Savara’s November 22, 2026, FDA decision date for MOLBREEVI in autoimmune pulmonary alveolar proteinosis was delayed, with no revised action date.
  • Phase 3 IMPALA-2 met its primary lung-function endpoint at week 24, with a 6-point DLCO advantage over placebo (p=0.0007).
  • The DLCO advantage reached 6.9 points at week 48 (p=0.0008); respiratory quality-of-life scores improved significantly at week 24 (p=0.0072).
  • Treatment discontinuation was 3%, with none attributed to drug-related adverse events.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief on November 20, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending